|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/573 | (2006.01) |
| A61K 31/454 | (2006.01) | ||
| A61K 31/69 | (2006.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 45/06 | (2006.01) |
| (11) | Number of the document | 2641601 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13168383.1 |
| Date of filing the European patent application | 2007-08-07 | |
| (97) | Date of publication of the European application | 2013-09-25 |
| (45) | Date of publication and mention of the grant of the patent | 2016-07-06 |
| (46) | Date of publication of the claims translation | 2016-10-10 |
| (30) | Number | Date | Country code |
| 836185 P | 2006-08-07 | US | |
| 944262 P | 2007-06-15 | US |
| (72) |
Afar, Daniel, US
Andersen, Kenneth C., US
Tai, Yu-Tzu, US
|
| (73) |
AbbVie Biotherapeutics Inc.,
1500 Seaport Boulevard, Redwood City, CA 94063,
US
Dana-Farber Cancer Institute, Inc., 450 Brookline Avenue, Boston, MA 02215, US |
| (74) |
Liucija JANICKAITĖ,
Inpatra UAB, Šeškinės g. 59-53, LT-07162 Vilnius,
LT
|
| (54) | Daugybinės mielomos, naudojant kombinuotas terapijas, pagrįstas HuLuc63 su bortezomibu, gydymo būdai |
| Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezomib |
| Payment date | Validity (years) | Amount | |
| 2025-07-10 | 19 | 347.00 EUR |
| 2026-08-07 |